AstraZeneca PLC (NASDAQ:AZN) Shares Bought by Goelzer Investment Management Inc.

Goelzer Investment Management Inc. raised its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 37.9% during the 4th quarter, Holdings Channel reports. The firm owned 83,689 shares of the company’s stock after buying an additional 22,983 shares during the quarter. Goelzer Investment Management Inc.’s holdings in AstraZeneca were worth $5,483,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. McClarren Financial Advisors Inc. boosted its position in AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after buying an additional 247 shares during the last quarter. Capital Performance Advisors LLP purchased a new position in AstraZeneca during the 3rd quarter worth approximately $28,000. Albion Financial Group UT lifted its stake in AstraZeneca by 68.9% during the 4th quarter. Albion Financial Group UT now owns 608 shares of the company’s stock valued at $40,000 after acquiring an additional 248 shares during the period. Groupama Asset Managment boosted its holdings in shares of AstraZeneca by 22.9% in the 3rd quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock valued at $42,000 after acquiring an additional 101,225 shares during the last quarter. Finally, Ashton Thomas Securities LLC acquired a new stake in shares of AstraZeneca in the third quarter worth $45,000. 20.35% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently issued reports on AZN shares. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Stock Up 0.7 %

AZN opened at $69.06 on Friday. The company has a fifty day moving average of $66.33 and a two-hundred day moving average of $74.24. The stock has a market capitalization of $214.16 billion, a price-to-earnings ratio of 33.04, a PEG ratio of 1.13 and a beta of 0.46. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93.

AstraZeneca (NASDAQ:AZN) last posted its earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. The firm had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company’s quarterly revenue was up 18.0% on a year-over-year basis. During the same period last year, the firm earned $0.87 EPS. On average, research analysts expect that AstraZeneca PLC will post 4.12 earnings per share for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.